M&T Bank Corp Pmv Pharmaceuticals, Inc. Transaction History

M&T Bank Corp

$28.6 Billion
Q1 2024

A detailed history of M&T Bank Corp transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 258,484 shares of PMVP stock, worth $418,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares

258,484

Previous 197,682 30.76%

Holding current value

$418,744

Previous $612,000 28.27%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$1.51 - $3.12 $91,811 - $189,702	60,802 Added 30.76%	258,484 $439,000
Q4 2023 Feb 06, 2024	BUY	$1.23 - $6.6 $243,148 - $1.3 Million	197,682 New	197,682 $612,000
Q1 2023 May 11, 2023	BUY	$4.77 - $9.16 $17,515 - $33,635	3,672 Added 8.87%	45,090 $215,000
Q4 2022 Feb 13, 2023	BUY	$8.17 - $12.95 $168,481 - $267,054	20,622 Added 99.16%	41,418 $360,000
Q4 2022 Feb 13, 2023	SELL	$8.17 - $12.95 $112,484 - $178,295	-13,768 Reduced 39.83%	20,796 $180,000

Q3 2022 Nov 14, 2022	SELL	$11.4 - $17.18 $3,990 - $6,013	-350 Reduced 1.0%	34,564 $412,000
Q2 2022 Aug 05, 2022	BUY	$9.23 - $22.43 $231,959 - $563,688	25,131 Added 256.88%	34,914 $498,000
Q1 2022 May 09, 2022	BUY	$14.86 - $23.55 $12,066 - $19,122	812 Added 9.05%	9,783 $204,000
Q4 2021 Feb 07, 2022	BUY	$19.99 - $30.24 $9,775 - $14,787	489 Added 5.77%	8,971 $207,000
Q3 2021 Oct 28, 2021	BUY	$26.84 - $36.58 $227,656 - $310,271	8,482 New	8,482 $253,000
Q1 2021 May 06, 2021	SELL	$30.66 - $49.5 $138,613 - $223,789	-4,521 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$31.86 - $61.51 $144,039 - $278,086	4,521 New	4,521 $278,000

Others Institutions Holding PMVP

# of Institutions

106

Shares Held

45.5M

Call Options Held

Put Options Held

600

View Full List

About PMV Pharmaceuticals, Inc.

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.9M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

More about PMVP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account